Evaxion is halting work on its infectious disease and autoimmune programs as the Danish biotech refocuses its R&D efforts solely on oncology.
The company's most advanced asset is a therapeutic cancer vaccine dubbed EVX-01 in phase 2 development for advanced melanoma. Evaxion's preclinical oncology pipeline also includes a pair of off-the-shelf vaccines for acute myeloid leukemia and glioblastoma, respectively, as well as a personalized, off-the-shelf vaccine for multiple cancer indications that is not yet disclosed.
In the company's third-quarter earnings results on Thursday, the biotech announced that it was going all-in on these immuno-oncology assets at the expense of its wider pipeline. This includes four preclinical infectious disease programs, spanning vaccines aimed at methicillin-resistant Staphylococcus aureus (MRSA), gonorrhea and cytomegalovirus.
An antibody binder and a tolerogenic vaccine, which are both aimed at autoimmune indications, have also been put on the back burner.
Evaxion will finalize the preclinical data packages for the infectious disease programs and actively look for partnerships for these assets “where the partner comes forward,” CEO Helen Tayton-Martin, Ph.D., explained on a Thursday morning call with analysts.
In the autoimmune space, Evaxion will continue to develop the assets in discovery and validate the vaccine approach for potential partnering in the future. The programs will only be taken forward if a partner is found, according to the company.
Evaxion ended September with $13.3 million in the bank, which the biotech expects to last through 2027.
“This is really about maximizing our own current resources around where we can see a lot of engagement and opportunity,” Tayton-Martin said on the call.
Evaxion’s AI-based immunology platform is designed to decode the human immune system to identify patient-specific antigens and develop novel immunotherapies. The biotech is also using the platform to drill into the dark genome—the name for the portion of DNA that does not directly code for proteins—to identify conserved antigens that can enable off-the-shelf vaccine opportunities across multiple cancer indications.
In August, the biotech scrapped its next-gen solid tumor vaccine in order to channel resources to a candidate specifically targeting brain cancer in collaboration with Duke University.
With the recent phase 3 win for Merck & Co. and Moderna's personalized cancer vaccine in melanoma, Evaxion hopes to ride this immune-oncology wave.
Earlier this month, Evaxion shared three-year follow-up data from the phase 2 study of EVX-01 that demonstrated an 89% vaccine target precision and sustained T-cell and clinical responses.
“With Moderna's recent phase 3 groundbreaking data validating personalized cancer vaccines as truly capable of delivering meaningful clinical benefit in adjuvant melanoma, we have been proud and excited to share our own phase 2 three-year clinical data in recent weeks,” Tayton-Martin said on this morning's call.